Cargando…

Optimizing the Safety Profile of Everolimus by Delayed Initiation in De Novo Heart Transplant Recipients: Results of the Prospective Randomized Study EVERHEART

BACKGROUND: Although everolimus potentially improves long-term heart transplantation (HTx) outcomes, its early postoperative safety profile had raised concerns and needs optimization. METHODS: This 6-month, open-label, multicenter randomized trial was designed to compare the cumulative incidence of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Potena, Luciano, Pellegrini, Carlo, Grigioni, Francesco, Amarelli, Cristiano, Livi, Ugolino, Maccherini, Massimo, Masciocco, Gabriella, Faggian, Giuseppe, Lilla della Monica, Paola, Gerosa, Gino, Marraudino, Nicola, Corda, Marco, Boffini, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Original Clinical Science—General
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828375/ https://www.ncbi.nlm.nih.gov/pubmed/28930797 http://dx.doi.org/10.1097/TP.0000000000001945

Ejemplares similares

COVID-19 in Heart Transplant Recipients: A Multicenter Analysis of the Northern Italian Outbreak
por: Bottio, Tomaso, et al.
Publicado: (2021)

Medium-term outcome of recipients of marginal donor hearts selected with new stress-echocardiographic techniques over standard criteria
por: Bombardini, Tonino, et al.
Publicado: (2014)

Usefulness and limitations of transthoracic echocardiography in heart transplantation recipients
por: Mondillo, Sergio, et al.
Publicado: (2008)

Steroid-free and steroid withdrawal protocols in heart transplantation: the review of literature
por: Baraldo, Massimo, et al.
Publicado: (2014)

Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients
por: Bergh, Niklas, et al.
Publicado: (2020)

Twelve-month effects of everolimus on renal and lung function in lung transplantation: differences in chronic lung allograft dysfunction phenotypes
por: Patrucco, Filippo, et al.
Publicado: (2021)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial
por: De Simone, P, et al.
Publicado: (2012)

Surgical management and outcomes in patients with acute type A aortic dissection and cerebral malperfusion
por: Vendramin, Igor, et al.
Publicado: (2022)

A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients
por: Chadban, Steven J, et al.
Publicado: (2014)

Everolimus induced pneumonitis in a lung transplant recipient
por: Arunachalam, Ambalavanan, et al.
Publicado: (2018)

Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR)
por: Brakemeier, Susanne, et al.
Publicado: (2019)

The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients
por: O'Leary, Jacqueline G., et al.
Publicado: (2016)

Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
por: Dal Moro, Fabrizio, et al.
Publicado: (2020)

Sutureless bioprostheses for aortic valve reoperations: How to get out of troubles
por: Vendramin, Igor, et al.
Publicado: (2022)

Introduction of everolimus in kidney transplant recipients at a late posttransplant stage
por: Uchida, Junji, et al.
Publicado: (2018)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
por: Wehming, Mathis, et al.
Publicado: (2023)

Everolimus‐facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2‐year results from the subgroup analysis of the TRANSFORM study
por: Watarai, Yoshihiko, et al.
Publicado: (2021)

The war against the SARS-CoV2 infection: Is it better to fight or mitigate it?
por: Dal Moro, Fabrizio, et al.
Publicado: (2020)

The Effect of Endurance Training on Pulmonary [Formula: see text] O(2) Kinetics in Solid Organs Transplanted Recipients
por: del Torto, Alessio, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Mycophenolic Acid as a Precision Medicine Tool for Heart Transplant Patients: Results of an Observational Pharmacokinetic Pilot Study
por: Lo Re, Francesco, et al.
Publicado: (2022)

Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation
por: Chapman, William C., et al.
Publicado: (2017)

Intermittent everolimus administration for malignant insulinoma
por: Baratelli, Chiara, et al.
Publicado: (2014)

Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients
por: Fuchs, Uwe, et al.
Publicado: (2012)

Everolimus and papillomavirus lesions in female renal transplant recipient: A case report
por: Simundic, T., et al.
Publicado: (2018)

1383. Everolimus is Associated with an Increased Risk of Tuberculosis in Solid-Organ Transplant Recipients
por: Sun, Hsin-Yun, et al.
Publicado: (2019)

The frequency of rare and monogenic diseases in pediatric organ transplant recipients in Italy
por: Vaisitti, Tiziana, et al.
Publicado: (2021)

The dawn of surgical treatment of aortic insufficiency
por: Vendramin, Igor, et al.
Publicado: (2022)

Pantoprazole Does not Affect Serum Trough Levels of Tacrolimus and Everolimus in Liver Transplant Recipients
por: Bremer, Sebastian C. B., et al.
Publicado: (2018)

Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients
por: Zwart, Tom C., et al.
Publicado: (2020)

Heart Transplantation in High-Risk Recipients Employing Donor Marginal Grafts Preserved With Ex-Vivo Perfusion
por: Sponga, Sandro, et al.
Publicado: (2023)

Covid-19 in recipients of heart and lung transplantation: Learning from experience
por: Kittleson, Michelle M., et al.
Publicado: (2021)

Functional and histological improvement after everolimus rescue of chronic allograft dysfunction in renal transplant recipients
por: Chow, Kai Ming, et al.
Publicado: (2015)

Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient Successfully Treated with Foscarnet and Everolimus
por: Menghi, Viola, et al.
Publicado: (2016)

Everolimus-associated alveolar hemorrage relapse after drug discontinuation in a kidney transplant recipient
por: Busutti, Marco, et al.
Publicado: (2022)

Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial
por: Nashan, Bjorn, et al.
Publicado: (2015)

Everolimus-Eluting Second-Generation Stents for Treatment of De Novo Lesions in Patients with Cardiac Allograft Vasculopathy
por: Pyka, Łukasz, et al.
Publicado: (2020)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

Everolimus for the treatment of CD20+ diffuse large B-cell lymphoma in a renal allograft recipient
por: Kute, V. B., et al.
Publicado: (2012)

Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients
por: Brunkhorst, Lena Caroline, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_atllh13rnqmkdm9m5joiqukg3n